|
|
|
|
November 17, 2024 -Sunday |
|
|
|
 |
| |
|
|
MOU SIGNING CEREMONY BETWEEN CLINICAL RESEARCH MALAYSIA - NOVOTECH - HEMATOGENIX
Friday 13/04/2018
MoU Signing Ceremony between Clinical Research Malaysia – Novotech – Hematogenix
Details of the event are as follows:
Day/Date : Friday 20 April 2018
Time: 9:00am – 10:30am
Venue: Dewan Putra Perdana 1, Level 1, Pulse Grande Hotel, Putrajaya
VIPs:
- YBhg Datuk Dr. Noor Hisham bin Abdullah, Director General of Health, Malaysia
- Mr. Zabidi Mahbar, Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA)
- Dr. Akhmal Yusof, Chief Executive Officer, Clinical Research Malaysia
- Dr. Yooni Kim, Executive Director, Asia Operations, Novotech
- Dr. Hytham Al-Masri, President & CEO of Hematogenix
Programme
9:00 am : Arrival of guests
9:15 am : Welcoming remarks by emcee
9:20 am : Remarks by Dr. Yooni Kim, Executive Director, Asia Operations, Novotech
9:30 am : Remarks by Dr. Hytham Al-Masri, President & CEO of Hematogenix
9.40 am : Remarks by En. Zabidi Mahbar, Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA)
9:50 am : Remarks by YBhg Datuk Dr. Noor Hisham bin Abdullah, Director General of Health, Malaysia
10:00 am : MoU Signing Ceremony
- Novotech and Clinical Research Malaysia (CRM)
- Hematogenix and Clinical Research Malaysia (CRM)
10:15 am : Press Conference
10:30 am : Adjourn for refreshments
Please RSVP your attendance to hamzah@clinicalresearch.my.
About Clinical Research Malaysia (CRM)
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to- end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.
About Novotech - www.novotech-cro.com
Established in 1996, Novotech is Australia’s largest independent contract research organization (CRO). Headquartered in Australia and focused exclusively on the Asia Pacific, Novotech is internationally recognized as a leading regional full-service CRO. With the increasing pace of globalization in drug development, Novotech’s expertise in the vibrant and fast growing Asian region has been instrumental in the success of hundreds of phase I-IV clinical trials from Australia to India. Novotech has its operations in New Zealand, China, Hong Kong, India, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand.
About Hematogenix
Hematogenix Laboratory Services® is expanding its global operations, and after a long search has chosen Malaysia. One of the pivotal factors in choosing Malaysia was the impressive help that has been provided by the Malaysian authorities.
Hematogenix Laboratory Services is a global CAP accredited and CLIA certified GCP-compliant cancer research and biotechnology company with locations in USA, Europe and soon Malaysia. Their medical laboratories focus on research and development of cancer related assays and work very closely, collaborate and provide consultation, guidance and testing services to global Pharma companies in Clinical Trials. The company offers a comprehensive array of biomarker development and testing services designed to navigate the complexities of human subject and advance our understanding of the molecular basis of cancer. Hematogenix delivers comprehensive services from Bio-Banking to Companion Diagnostics and clinical trial services as well as provides logistic management of tissue, distributes collection kits, and contributes to standards and procedures required for initiating clinical trials. Powered by a state-of-the-art laboratory information system, Hematogenix facilities and practices comply with a rigorous chain of custody and specimen management practices. Services include Flow Cytometry, Companion Diagnostics Development, Assay Development, IHC, FISH, ISH, Next Generation Sequencing (NGS), Real-Time PCR, PCR, mRNA ISH, and Cytogenetics.
You are cordially invited to send a reporter and photographer/cameraman to cover the event.
Source: Clinical Research Malaysia (CRM)
FOR MORE INFORMATION AND RSVP PLEASE CONTACT:
Name: Syed Hamzah Syed Noordin
Tel : +603 7960 5153 (121)
Email : hamzah@clinicalresearch.my
Website : http://www.clinicalresearch.my
-BERNAMA |
|
|
|
|
|
